Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06551519 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

Study acronym: FILAXOS
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites reduced: 89 → 82 locations Enrollment target: 489 to 519 · Start date: Oct 28, 2024 to Oct 23, 2024 · Eligibility criteria expanded, about 6 words · 1 more Show 4 more changesShow less
    • Enrollment target: 489 to 519
    • Start date: Oct 28, 2024 to Oct 23, 2024
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 5 of 16 entries
  2. Enrollment reduced: 700 → 489 participants Trial status changed: Recruiting → Active, Not Recruiting · Trial sites reduced: 109 → 89 locationsv8 Show 2 more changesShow less
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Trial sites reduced: 109 → 89 locations
  3. Site details revised at 4 of 109 sitesv7
  4. Study sites: 108 to 109v6
  5. Enrollment target: 900 to 700 Study sites: 104 to 108 · Start date: Oct 23, 2024 to Oct 28, 2024v5 Show 2 more changesShow less
    • Study sites: 104 to 108
    • Start date: Oct 23, 2024 to Oct 28, 2024
Show 3 earlier versionsHide 3 earlier versions
  1. Primary and study completion dates: Sep 16, 2027 to Nov 29, 2028 Study sites: 26 to 104v4 Show 1 more changeShow less
    • Study sites: 26 to 104
  2. Study sites: 2 to 26v3
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Primary and study completion dates: Aug 30, 2027 to Sep 16, 2027 · Start date changed from estimate of Aug 30, 2024 to Oct 23, 2024v2 Show 3 more changesShow less
    • Study sites: 0 to 2
    • Primary and study completion dates: Aug 30, 2027 to Sep 16, 2027
    • Start date changed from estimate of Aug 30, 2024 to Oct 23, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
Multiple Sclerosis
991 trials monitored
See 36 trials at risk
This is a prospective, multicenter, observational, non-interventional study (NIS) in patients with Multiple Sclerosis (MS) and routinely assessed serum neurofilament light (sNfL) values in Germany
Trial Details
NCT Number NCT06551519
Lead Sponsor Novartis Pharmaceuticals
Conditions Multiple Sclerosis
Enrollment 519 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov